search
Back to results

Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients (PCS)

Primary Purpose

Acute Respiratory Failure, Anxiety

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Dexmedetomidine
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Respiratory Failure focused on measuring sedation, mechanical ventilation, anxiety, respiratory failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult intubated patients with respiratory failure expected to require mechanical ventilation for at least an additional 48 hours
  • subjects have to have at least a 50% chance of being able to operate the PCS machine (i.e., adequate hand strength and cognition)

Exclusion Criteria:

  • aggressive ventilatory support such as positive end expiratory pressure > 15 cm of water, prone ventilation, use of high-frequency oscillator ventilator
  • hypotension requiring vasopressors (systolic blood pressure < 85 mmHg), second or third degree heart block or bradycardia (heart rate < 50 beats/min.)
  • permanent condition preventing the use of push button device (e.g., paralysis)
  • pregnancy or lactation
  • acute hepatitis or liver failure
  • general anesthesia 24 hours prior
  • acute stroke or uncontrolled seizures
  • acute MI
  • severe cognition or communication problems (e.g., coma as main reason for intubation, deafness without signing literacy, dementia or severe delirium)

Sites / Locations

  • University of Minnesota Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

usual sedative practice

Patient controlled sedation

Arm Description

Subjects will have "usual care" sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration.

Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.

Outcomes

Primary Outcome Measures

Aggregate Sedative Exposure During PCS Use (up to 5 Days).
Will use the sedation intensity score Scale is based on a score of 1 (full arousal) to 4 (no arousal)

Secondary Outcome Measures

Number of Participants With Adverse Events
arterial hypotension, bradycardia, self-extubations, and protocol violations related to drug, pump or both.

Full Information

First Posted
April 9, 2012
Last Updated
February 13, 2018
Sponsor
University of Minnesota
Collaborators
National Institute of Nursing Research (NINR), Hospira, now a wholly owned subsidiary of Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT01606852
Brief Title
Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients
Acronym
PCS
Official Title
Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota
Collaborators
National Institute of Nursing Research (NINR), Hospira, now a wholly owned subsidiary of Pfizer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Mechanical ventilation (MV) is the most frequently used life-support modality in intensive care units (ICUs). To reduce anxiety, stress and promote tolerance of MV, nurses frequently administer a variety of sedative medications to their patients based on subjective observations. The investigators hypothesize that patient-controlled sedation, compared to clinician-directed sedation, will decrease sedative exposure while decreasing patient anxiety during the episode of mechanical ventilation.
Detailed Description
A study to determine whether critically ill patients, during a substantial portion of their time on mechanical ventilation, can reduce anxiety symptoms better with PCS than their caregivers while reducing over-sedation, duration of mechanical ventilation and length of ICU stay will require hundreds of subjects enrolled on a multi-day protocol. However, patient-controlled sedation has been used in less than 20 patients and only for less than 24 hours. Therefore this study is designed to: Establish the feasibility of subject recruitment and protocol adherence in a randomized pilot trial that compares patient-controlled sedation (PCS) using dexmedetomidine to usual sedation practice in mechanically ventilated patients. Feasibility will be defined by: a) number and proportion of patients or proxies who consent to enrollment, b) proportion of eligible subjects enrolled on Days 1,2,3,4 etc, of mechanical ventilation, c) number of days on protocol, up to five days, that subjects successfully use the PCS device, d) ability of ICU nurses to adjust the pump and adhere to the infusion rates of the PCS protocol. Develop and refine the study protocol including: a) improving the proportion of patient daily assessments actually completed such as anxiety and delirium scales, b) develop a protocol to reliably determine when the subject is not able to self-manage their sedation due to weakness, confusion or severe illness; c) create rules for suspending PCS therapy and d) develop a post-ICU symptom interview. Estimate effect sizes on key variables to inform the design of a future randomized trial to compare: a) sedative exposure, anxiety levels, and delirium occurrence between groups, b) adverse event rates and protocol violations related to the drug, pump or both; and c) duration of mechanical ventilation and ICU stay.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Respiratory Failure, Anxiety
Keywords
sedation, mechanical ventilation, anxiety, respiratory failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
usual sedative practice
Arm Type
No Intervention
Arm Description
Subjects will have "usual care" sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration.
Arm Title
Patient controlled sedation
Arm Type
Experimental
Arm Description
Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Other Intervention Name(s)
Administered via a Lifecare PCA Infusion System (Hospira)
Intervention Description
loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
Primary Outcome Measure Information:
Title
Aggregate Sedative Exposure During PCS Use (up to 5 Days).
Description
Will use the sedation intensity score Scale is based on a score of 1 (full arousal) to 4 (no arousal)
Time Frame
5 days after enrollment
Secondary Outcome Measure Information:
Title
Number of Participants With Adverse Events
Description
arterial hypotension, bradycardia, self-extubations, and protocol violations related to drug, pump or both.
Time Frame
During 5 days of study protocol

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult intubated patients with respiratory failure expected to require mechanical ventilation for at least an additional 48 hours subjects have to have at least a 50% chance of being able to operate the PCS machine (i.e., adequate hand strength and cognition) Exclusion Criteria: aggressive ventilatory support such as positive end expiratory pressure > 15 cm of water, prone ventilation, use of high-frequency oscillator ventilator hypotension requiring vasopressors (systolic blood pressure < 85 mmHg), second or third degree heart block or bradycardia (heart rate < 50 beats/min.) permanent condition preventing the use of push button device (e.g., paralysis) pregnancy or lactation acute hepatitis or liver failure general anesthesia 24 hours prior acute stroke or uncontrolled seizures acute MI severe cognition or communication problems (e.g., coma as main reason for intubation, deafness without signing literacy, dementia or severe delirium)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Craig Weinert, MD
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients

We'll reach out to this number within 24 hrs